DDInter248 DDInter1660
Bumetanide is a sulfamyl diuretic.
Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017. The tablet formulation was approved for oral administration in September 2019. Semaglutide works by binding to and activating the GLP-1 receptor, thereby stimulating insulin secretion and reducing blood glucose. The subcutaneous injection is administered once weekly and the tablet is administered once a day. Semaglutide offers a competitive advantage over other drugs used to manage diabetes, which may require several daily doses. Clinical trials have determined that this drug reduces glycosylated hemoglobin (HbA1c) levels and reduces body weight, proving to be effective for patients with type 2 diabetes. In June 2021, semaglutide was approved by the FDA for chronic weight management in adults with general obesity or overweight who have at least one weight-related condition, marking semaglutide as the first approved drug for such use since 2014. The use of semaglutide in weight management is also approved by Health Canada and the EMA. On May 31, 2023, the FDA issued a warning regarding the use of compounded semaglutide after receiving adverse event reports. The use of salt forms of semaglutide, including semaglutide sodium and semaglutide acetate, has not been proven to be safe or effective.
Bumetanide {u} (Compound) resembles {v} (Compound) Indapamide
Indapamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Bumetanide {u} (Compound) resembles {v} (Compound) Furosemide
Furosemide {u} (Compound) resembles {v} (Compound) Indapamide
Indapamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Bumetanide {u} (Compound) resembles {v} (Compound) Indapamide
Indapamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Prednisolone
Prednisolone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Bumetanide {u} (Compound) treats {v} (Disease) hypertension
hypertension {u} (Disease) is treated by {v} (Compound) Chlorothiazide
Chlorothiazide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Bumetanide {u} (Compound) resembles {v} (Compound) Indapamide
Indapamide {u} (Compound) resembles {v} (Compound) Metolazone
Metolazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Bumetanide {u} (Compound) binds {v} (Gene) CA12
CA12 {u} (Gene) is bound by {v} (Compound) Metolazone
Metolazone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Bumetanide {u} (Compound) resembles {v} (Compound) Indapamide
Indapamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Nateglinide
Nateglinide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Bumetanide {u} (Compound) binds {v} (Gene) PTGS2
PTGS2 {u} (Gene) is upregulated by {v} (Compound) Omacetaxine mepesuccinate
Omacetaxine mepesuccinate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Bumetanide {u} (Compound) palliates {v} (Disease) chronic kidney failure
chronic kidney failure {u} (Disease) is palliated by {v} (Compound) Etacrynic acid
Etacrynic acid {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Bumetanide {u} (Compound) is included by {v} (Pharmacologic Class) Increased Diuresis at Loop of Henle
Increased Diuresis at Loop of Henle {u} (Pharmacologic Class) includes {v} (Compound) Torasemide
Torasemide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Semaglutide
Bumetanide (Compound) resembles Indapamide (Compound) and Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Bumetanide (Compound) resembles Furosemide (Compound) and Furosemide (Compound) resembles Indapamide (Compound) and Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Bumetanide (Compound) resembles Indapamide (Compound) and Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Bumetanide (Compound) treats hypertension (Disease) and hypertension (Disease) is treated by Chlorothiazide (Compound) and Chlorothiazide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Bumetanide (Compound) resembles Indapamide (Compound) and Indapamide (Compound) resembles Metolazone (Compound) and Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Bumetanide (Compound) binds CA12 (Gene) and CA12 (Gene) is bound by Metolazone (Compound) and Metolazone may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Bumetanide (Compound) resembles Indapamide (Compound) and Indapamide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Bumetanide (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound) and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Bumetanide (Compound) palliates chronic kidney failure (Disease) and chronic kidney failure (Disease) is palliated by Etacrynic acid (Compound) and Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Bumetanide (Compound) is included by Increased Diuresis at Loop of Henle (Pharmacologic Class) and Increased Diuresis at Loop of Henle (Pharmacologic Class) includes Torasemide (Compound) and Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide